The Return of Part 11
This article was originally published in The Gold Sheet
Executive Summary
FDA July 7 alerted industry that the agency will soon begin conducting inspections focused on compliance with its March 1997 Part 11 rule on electronic records and electronic signatures
You may also be interested in...
Latest FDA Drug GMP Warning Letters Target CEOs, Contract Manufacturers
Six of FDA's last nine drug GMP warning letters went to contract manufacturing facilities, including firms making OTC drugs and dietary supplements.
CEOs and Contract Manufacturers Targeted in Latest Warning Letters
FDA sent six of its last nine drug GMP warning letters to contract manufacturing facilities. Most of the letters emphasized corporate accountability, and many went directly to CEOs.
Japan Regulatory Update: Revised Law Widens RWD Scope, Price Revisions/Listings
Japan now allows pseudonymized personal data for medical use under a licensing system for wider use of real-world data. Meanwhile, a national cost-effectiveness assessment scheme has slashed reimbursement prices for Lagevrio and Kerendia, and Alexion’s Voydeya has been added to the reimbursement tariff.